首页> 外国专利> PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING PIRFENIDONE IN SUSTAINED-RELEASE TABLET FORM AND ITS APPLICATION IN THE REGRESSION OF HUMAN CHRONIC RENAL FAILURE, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS

PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING PIRFENIDONE IN SUSTAINED-RELEASE TABLET FORM AND ITS APPLICATION IN THE REGRESSION OF HUMAN CHRONIC RENAL FAILURE, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS

机译:持续释放片剂形式的包含吡非尼酮的药物组合物的制备方法及其在人类慢性肾功能衰竭,乳腺癌,乳糜泻和肝纤维化中的应用

摘要

The present invention relates to a method for manufacturing a pharmaceutical composition in the form of extended-release tablets that include from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), such that the drug containing same is bioavailable during an extended period of 12 hours from the administration thereof. This optimizes the anti-fibrotic and anti-inflammatory action of the Pirfenidone. Additionally, the present invention offers advantages and better therapeutic effectiveness over other pharmaceutical forms of Pirfenidone for oral administration and the therapeutic use thereof in the regression of chronic secondary renal insufficiency to primary glomerulosclerosis; it shows greater activity in the decrease and/or regression of the toxic effects on the breast capsular contracture observed after surgical implantation of breast implants in humans and exercises a significant anti-TNF-a and anti-TGF-ß? action in the treatment of hepatic fibrosis.
机译:本发明涉及一种用于制备包含600毫克至2400毫克吡非尼酮(PFD)的缓释片剂形式的药物组合物的方法,从而使得包含该药物的药物在自12小时的延长时间内可生物利用。其管理。这优化了吡非尼酮的抗纤维化和抗炎作用。另外,本发明相对于口服吡非尼酮的其他药物形式及其在慢性继发性肾功能不全向原发性肾小球硬化的消退中的治疗用途提供了优于吡非尼酮的其他优点和更好的治疗效果。它显示出更大的活性,可以降低人体内植入乳房假体后对乳房荚膜挛缩的毒性作用的减少和/或消退,并具有显着的抗TNF-α和抗TGF-β活性。在治疗肝纤维化中的作用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号